SCHEMBL3548310

SCHEMBL3548310

COC(=O)C(=O)Nc1cnc(N2CCN(C(=O)O)C(C(C)(C)C)C2)nc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.39
DGAT1 O75907 2/20 0.35
KIT P10721 2/20 0.35
LIMK2 P53671 1/20 0.34
CHRM1 P11229 4/20 0.34
CHRM2 P08172 3/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
DGAT2 Q96PD7 1/20 0.34
CHRM4 P08173 3/20 0.33
CHRM3 P20309 3/20 0.33
GPR119 Q8TDV5 2/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
CHRM5 P08912 1/20 0.33
PTPN11 Q06124 1/20 0.33
OGA O60502 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22519008 0.79 CHRM1 (0.46) SLC6A7CHRM1CHRM2CHRM4CHRM3
SCHEMBL25264632 0.76 CHRM4 (0.48) SLC6A7CHRM1CHRM2CHRM4CHRM3
SCHEMBL25383375 0.74 SLC6A7 (0.45) SLC6A7LMNAHPGDCHRM4
SCHEMBL29029916 0.73 SLC6A7 (0.38) SLC6A7LIMK2CHRM1CHRM2CHRM4
SCHEMBL5326030 0.73 PTPN11 (0.53) DGAT1GPR119PTPN11
SCHEMBL13009501 0.73 PTPN11 (0.47) DGAT1LMNAHPGDPTPN11OGA
SCHEMBL5222720 0.72 HDAC1 (0.48) SLC6A7KITDGAT2CHRM4PTPN11
SCHEMBL28695335 0.72 SLC6A7 (0.37) SLC6A7DGAT1CHRM1CHRM2CHRM4
Hydrochloric Acid SCHEMBL3540138 0.70 ALDH1A1 (0.44) HPGD
SCHEMBL1449587 0.70 GPR119 (0.50) SLC6A7CHRM4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 SLC6A7 753/4885DGAT1 1/4885KIT 4522/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 SLC6A7 683/4885DGAT1 1/4885KIT 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.